ARCHIVES

Iressa Authorization In Europe Clarifies Differences Between U.S., E.U. Standards

This article is from The Cancer Letter archive.

Vol. 35 No. 30 | July 31, 2009

Download PDF Visit The Full Archive

Related Articles

NIH, NCI Get Higher Funding In 2014 Budget

January 17, 2014

FDA Advisors Recommend Approval Of Topotecan for Ovarian Cancer

April 26, 1996

Slow Accruing Trials Should Be Removed From High Priority Program, Broder Says

October 2, 1992

HHS Inspector General: IRBs Vulnerable In Changing Research Environment-Report

July 10, 1998

In Brief: CDP Services Wins ASC Planning Contract; Jury Finds Sarin Guilty of Embezzlement

July 17, 1992

CCOPs At Six Months: Sme Exceeding Patient Goals, Most Are Meeting Schedules

March 30, 1984